Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Medicine

Exploring Artificial Intelligence Models for the Detection and Prediction of Sarcopenia: A Scoping Review

11 affiliations
  1. 1Hospital Nacional de Geriatría y Gerontología, Caja Costarricense del Seguro Social, San José 10103, Costa Rica
  2. 2Grupo de Estudios del Envejecimiento (GEE), Santiago 7500975, Chile
  3. 3Complejo Asistencial Dr. Sótero del Río, Santiago 8207257, Chile
  4. 4Centro de Rehabilitación La Florida, Caja de Previsión de la Defensa Nacional (CAPREDENA), Santiago 8310473, Chile
  5. 5Programa de Especialidad de Geriatría, Universidad de Santiago de Chile, Santiago 7500975, Chile
  6. 6Programa de Doctorado en Bienestar Humano, Salud y Sociedad, Facultad de Salud y Ciencias Sociales, Universidad de Las Americas (UDLA), Santiago 7500975, Chile
  7. 7Unidad de Investigación en Salud, Hospital Nacional de Geriatría y Gerontología, Caja Costarricense del Seguro Social, San José 10103, Costa Rica
  8. 8Faculty of Medicine, Andrés Bello University, Santiago 8370146, Chile
  9. 9Department of Chemical and Biological Sciences, Faculty of Health Sciences, Bernardo O’Higgins University, Santiago 8370933, Chile
  10. 10GIAVAL Research Group, Department of Anatomy and Human Embryology, Faculty of Medicine, University of Valencia, 46001 Valencia, Spain
  11. 11Grupo de Investigación Bienestar, Salud y Sociedad, Escuela de Psicología y Educación, Universidad de Las Américas, Quito 170124, Ecuador

Abstract

Background/Objectives: Sarcopenia is a progressive skeletal muscle disorder associated with adverse health outcomes, including disability, hospitalization, and mortality. Despite the availability of consensus-based diagnostic criteria, its identification in clinical practice remains limited due to reliance on specialized assessments and resource-intensive measurements. Artificial intelligence (AI) and machine learning (ML) approaches have emerged as promising tools to enhance sarcopenia detection; however, evidence remains methodologically heterogeneous and has not been comprehensively synthesized. The objective was to systematically map the existing literature on AI/ML models developed to detect or predict sarcopenia, describing their methodological characteristics, input features, model performance, validation strategies, and adherence to reporting standards. Methods: A scoping review was conducted following PRISMA-ScR guidelines. Searches were performed in five databases (MEDLINE, Scopus, SciELO, Web of Science, and LILACS) from inception to 28 February 2026. Studies were included if they developed and/or validated AI/ML models for binary classification of sarcopenia using recognized consensus definitions. Two reviewers independently screened studies, extracted data, and assessed adherence to TRIPOD+AI reporting recommendations and appraised methodological quality using the NHLBI Quality Assessment Tool. Findings were synthesized descriptively. The review protocol was registered in the Open Science Framework. Results: Of 2910 records, 28 studies (n = 34,498 participants in the primary analytical cohorts, with an additional 2800 participants in independent external validation cohorts) were included, predominantly from Asia (China n = 14, South Korea n = 7). Random Forest was the most frequent algorithm (n = 6), followed by voting classifiers, MLP, and XGBoost (n = 4 each). Clinical tabular data, including anthropometric and laboratory variables, were the most common input features. Model performance was generally high, with AUC values ranging from 0.710 to 0.975 (mean ≈ 0.869), although heterogeneity across populations and validation strategies was substantial. External validation was performed in only 7 of the 28 studies (25%). No study fully adhered to TRIPOD+AI recommendations; mean compliance was moderate, with critical gaps in code sharing, patient/public involvement, external validation, and subgroup performance reporting. Conclusions: AI/ML models, particularly ensemble methods using accessible clinical variables, showed high discrimination in model development settings, with performance estimates that derive predominantly from internal validation and are not comparable across studies. However, important methodological limitations, including lack of external validation, limited generalizability, and suboptimal adherence to reporting standards, were observed. Future research should prioritize external validation in diverse populations, transparent reporting following TRIPOD+AI, and open sharing of code and data to facilitate clinical translation.

Related

  1. Artificial Intelligence-Enhanced Electrocardiography for Detection and Prediction of Hypertrophic Cardiomyopathy across Monogenic and Polygenic Susceptibility
    P. M. Croon, R. B. Choi, E. K. Oikonomou +11
    medRxivPreprintAll rights reservedFull textCardiovascular medicinemedRxiv
  2. Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography–segmentation and a geriatric assessment
    Samuel J. Yates, Elizabeth Terman, Lauren Miller +17
    LeukemiaPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  3. Exploring nursing students' communication experiences with artificial intelligence-supported virtual patients: a qualitative study.
    Ayşegül Korkmaz Doğdu, Ayşe Dağistan Akgöz
    BMC nursingPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMC
  4. Artificial Intelligence-Enhanced Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy: Diagnosis, Phenotypic Characterization, and Risk Prediction
    Yu-Jie Xiang, Yu-Cong Zheng, Ju Han +3
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Use of multi-modal artificial intelligence model for prediction of atrial fibrillation in hospitalized patients
    Unmesh Khanolkar, Ashish Yadav, Avdhesh Mann +6
    Heart rhythm O2Peer-reviewedCC BY-NC-NDFull textCardiovascular medicineEurope PMC
BibTeX
@article{solanosandi2026exploring,
  title = {{Exploring Artificial Intelligence Models for the Detection and Prediction of Sarcopenia: A Scoping Review}},
  author = {Luis Armando Solano-Sandi and Eduardo Gallegos and Cristian Barros-Osorio and Jennifer Campos-Aguayo and Isabel Barrientos-Calvo and Fernanda García and Juan José Valenzuela Fuenzalida and Juan Sanchis-Gimeno and Jose E. León-Rojas and Walter Sepúlveda-Loyola},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  month = oct,
  doi = {10.3390/jcm15218320},
  url = {https://www.mdpi.com/2077-0383/15/21/8320},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Exploring Artificial Intelligence Models for the Detection and Prediction of Sarcopenia: A Scoping Review
AU  - Luis Armando Solano-Sandi
AU  - Eduardo Gallegos
AU  - Cristian Barros-Osorio
AU  - Jennifer Campos-Aguayo
AU  - Isabel Barrientos-Calvo
AU  - Fernanda García
AU  - Juan José Valenzuela Fuenzalida
AU  - Juan Sanchis-Gimeno
AU  - Jose E. León-Rojas
AU  - Walter Sepúlveda-Loyola
PY  - 2026
DA  - 2026/10/26
JO  - Journal of Clinical Medicine
DO  - 10.3390/jcm15218320
UR  - https://www.mdpi.com/2077-0383/15/21/8320
AB  - Background/Objectives: Sarcopenia is a progressive skeletal muscle disorder associated with adverse health outcomes, including disability, hospitalization, and mortality. Despite the availability of consensus-based diagnostic criteria, its identification in clinical practice remains limited due to reliance on specialized assessments and resource-intensive measurements. Artificial intelligence (AI) and machine learning (ML) approaches have emerged as promising tools to enhance sarcopenia detection; however, evidence remains methodologically heterogeneous and has not been comprehensively synthesized. The objective was to systematically map the existing literature on AI/ML models developed to detect or predict sarcopenia, describing their methodological characteristics, input features, model performance, validation strategies, and adherence to reporting standards. Methods: A scoping review was conducted following PRISMA-ScR guidelines. Searches were performed in five databases (MEDLINE, Scopus, SciELO, Web of Science, and LILACS) from inception to 28 February 2026. Studies were included if they developed and/or validated AI/ML models for binary classification of sarcopenia using recognized consensus definitions. Two reviewers independently screened studies, extracted data, and assessed adherence to TRIPOD+AI reporting recommendations and appraised methodological quality using the NHLBI Quality Assessment Tool. Findings were synthesized descriptively. The review protocol was registered in the Open Science Framework. Results: Of 2910 records, 28 studies (n = 34,498 participants in the primary analytical cohorts, with an additional 2800 participants in independent external validation cohorts) were included, predominantly from Asia (China n = 14, South Korea n = 7). Random Forest was the most frequent algorithm (n = 6), followed by voting classifiers, MLP, and XGBoost (n = 4 each). Clinical tabular data, including anthropometric and laboratory variables, were the most common input features. Model performance was generally high, with AUC values ranging from 0.710 to 0.975 (mean ≈ 0.869), although heterogeneity across populations and validation strategies was substantial. External validation was performed in only 7 of the 28 studies (25%). No study fully adhered to TRIPOD+AI recommendations; mean compliance was moderate, with critical gaps in code sharing, patient/public involvement, external validation, and subgroup performance reporting. Conclusions: AI/ML models, particularly ensemble methods using accessible clinical variables, showed high discrimination in model development settings, with performance estimates that derive predominantly from internal validation and are not comparable across studies. However, important methodological limitations, including lack of external validation, limited generalizability, and suboptimal adherence to reporting standards, were observed. Future research should prioritize external validation in diverse populations, transparent reporting following TRIPOD+AI, and open sharing of code and data to facilitate clinical translation.
SN  - 2077-0383
ER  -